Novasep to expand in HPAPIs
€3 million investment targets novel anti-cancer therapies
Novasep has announced plans to invest €3 million to expand its high potency API (HPAPI) facility at its SafeBridge-certified facility in Le Mans, France. This is mainly targeted at increasing demand for HPAPIs in targeted and potent drugs for the treatment of cancer. The company said that it will add to its comprehensive capabilities in the synthesis of antibody-drug conjugates (ADCs), including toxin and monoclonal antibody (mAb) production, mAb-toxin coupling, downstream processing, and formulation.
The new facility should be fully operational in early 2013. It will feature cryogenic chemistry at -60°C in Hastelloy reactors, large-scale HPLC chromatography and drying in confined areas to manufacture ADC toxins at commercial scale, as well as the synthesis, purification and isolation of multi-kilo batches of extremely potent compounds with an occupational exposure limit (OEL) of <30 ng/m3.